Accordingly, the blockade of interaction between CTLA-4 and CD80/CD86 or PD-1 with PD-L1/PD-L2 is able to increase the immune response against tumor cells, exerting thus a significant therapeutic effect4. The gene discussed is CD274; the disease is neoplasm.